Prospective analysis of circulating metabolites and endometrial cancer risk. in Gynecologic oncology / Gynecol Oncol. 2021 Aug;162(2):475-481. doi: 10.1016/j.ygyno.2021.06.001. Epub 2021 Jun 5.

2021
AOU Città della Salute di Torino

Tipo pubblicazione

Research Support, Non-U.S. Gov't

Autori/Collaboratori (36)Vedi tutti...

Christakoudi S
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; MRC Centre for Transplantation, King's College London, London, UK.
Tsilidis KK
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Travis RC
Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

et alii...

Abstract

BACKGROUND: Endometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy. To identify additional novel metabolic pathways associated with endometrial cancer we performed metabolomic analyses on pre-diagnostic plasma samples from 853 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC). METHODS: A total of 129 metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexoses, and sphingolipids) were measured by liquid chromatography-mass spectrometry. Conditional logistic regression estimated the associations of metabolites with endometrial cancer risk. An analysis focusing on clusters of metabolites using the bootstrap lasso method was also employed. RESULTS: After adjustment for body mass index, sphingomyelin [SM] C18:0 was positively (OR(1SD): 1.18, 95% CI: 1.05-1.33), and glycine, serine, and free carnitine (C0) were inversely (OR(1SD): 0.89, 95% CI: 0.80-0.99; OR(1SD): 0.89, 95% CI: 0.79-1.00 and OR(1SD): 0.91, 95% CI: 0.81-1.00, respectively) associated with endometrial cancer risk. Serine, C0 and two sphingomyelins were selected by the lasso method in >90% of the bootstrap samples. The ratio of esterified to free carnitine (OR(1SD): 1.14, 95% CI: 1.02-1.28) and that of short chain to free acylcarnitines (OR(1SD): 1.12, 95% CI: 1.00-1.25) were positively associated with endometrial cancer risk. Further adjustment for C-peptide or other endometrial cancer risk factors only minimally altered the results. CONCLUSION: These findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.

Accesso banca dati bibliografica

Accedi alla scheda bibliografica del documento in PUBMED

Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.

PMID : 34099314

DOI : 10.1016/j.ygyno.2021.06.001

Keywords

Metabolomics; Obesity; Lipids; Endometrial cancer; Amino acids; Sphingomyelins/blood/metabolism; Serine/blood/metabolism; Risk Factors; Prospective Studies; Middle Aged; Metabolomics; Humans; Female; Glycine/blood/metabolism; Endometrial Neoplasms/blood/diagnosis/epidemiology/metabolism; Case-Control Studies; Carnitine/blood/metabolism; Body Mass Index; Biomarkers, Tumor/blood/metabolism; Aged;